Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

@article{Balak2012CutaneousAE,
  title={Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review},
  author={D. Balak and G. Hengstman and Aysun Çakmak and H. B. Thio},
  journal={Multiple Sclerosis Journal},
  year={2012},
  volume={18},
  pages={1705 - 1717}
}
  • D. Balak, G. Hengstman, +1 author H. B. Thio
  • Published 2012
  • Medicine
  • Multiple Sclerosis Journal
    • Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS). DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life. In this systematic review, we aimed to provide an overview of the clinical spectrum and the incidence of skin reactions associated with DMTs. A systematic literature search was performed up to May 2011 in Medline, Embase, and Cochrane databases… CONTINUE READING
    View on SAGE
    repub.eur.nl
    49 Citations
    Highly Influencial Citations
    4
    Background Citations
    26
    Methods Citations
    2

    Paper Mentions

    Interventional Clinical Trial
    Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions
    Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via… Expand
    ConditionsAutoimmune, Multiple Sclerosis
    InterventionDevice, Procedure
    Healeon Medical Inc
    September 2016 - October 2023
    49 Citations
    Citation Type

    Citation Type

    Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
    • 9
    • PDF
    Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
    • 16
    • Highly Influenced
    • PDF
    A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
    • 30
    • PDF
    Interferon-beta injection site reactions in patients with multiple sclerosis
    • 2
    Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.
    • 10
    • PDF
    Patterns of local site reactions to subcutaneous glatiramer acetate treatment of multiple sclerosis: a clinicopathological study.
    • 1
    • PDF
    Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis
    • 19
    The heritage of glatiramer acetate and its use in multiple sclerosis
    • 9
    An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
    • 3
    Hypocomplementemic urticarial vasculitis and multiple Sclerosis: A rare association or an atypical presentation?
    • 2

    References

    SHOWING 1-10 OF 142 REFERENCES
    Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management
    • 41
    [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices].
    • 32
    Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b.
    • 20
    Interferon in relapsing-remitting multiple sclerosis.
    • 152
    A longitudinal observational study of a cohort of patients with relapsing–remitting multiple sclerosis treated with glatiramer acetate
    • 15
    [Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis].
    • 5
    Lipoatrophy: a non–reversible complication of subcutaneous interferon–beta 1a treatment of multiple sclerosis
    • 14
    Vitiligo and multiple sclerosis in a patient treated with interferon beta‐1a: a case report
    • 21
    [Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon beta-1b].
    • 3
    Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
    • 467
    • PDF